1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Novacyt S.A.

Novacyt S.A.

NVYTF
Novacyt S.A.US flagOther OTC
0.48
USD
-NaN
- -
34.80MMarket Cap
Novacyt S.A.
NVYTF
(Other OTC)

Recent

price

0.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.28
0.33
329.93
0.8
0.97
0.78
0.5
0.33
0.25
4.07
1.31
0.3
0.15
0.28
0.28
Revenue per Share
-0.21
-0.17
-284.76
-0.69
-1.51
-0.4
-0.21
-0.11
-0.13
1.94
-0.14
-0.36
-0.4
-0.59
-0.32
Basic EPS, GAAP
-0.24
-0.24
-505.62
-0.47
-0.67
-0.22
-0.22
-0.05
-0.03
1.49
0.16
-0.2
-0.33
-0.16
-0.14
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.17
-0.11
-1,173.91
-1.37
-2.36
-1.88
-1.21
-0.66
-0.72
1.48
1.29
0.93
0.48
-0.11
-0.69
Book Value per Share
-0.43
0.21
342.79
0.02
- -
-0.28
0.14
-0.02
-0.11
1.89
1.79
1.49
0.79
0.39
0.28
Tangible Book Value per Share
3
3
- -
4
7
12
23
38
46
68
71
71
71
71
71
Basic Weighted Avg Shares
1
1
1
4
7
9
11
12
11
277
93
21
11
20
20
Sales/Revenue/Turnover
-75.02
-51.94
-120.62
-53.16
-34.12
-26.97
-0.27
-3.8
-9.24
63.1
1.53
-74.5
-149.02
17.14
-61.8
Operating Margin (%)
- -
- -
- -
- -
7
1
1
1
2
8
8
8
10
- -
19
Depreciation Expense
-1
- -
-1
-3
-10
-5
-5
-4
-6
132
-10
-26
-28
-42
-23
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
19.83
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-74.93
-50.47
-86.31
-86.43
-156.41
-51.55
-42.69
-34.53
-50.13
47.77
-10.51
-122.29
-266.38
-212.73
-114.25
Profit Margin (%)
-1
1
1
1
1
-1
3
- -
- -
131
120
103
57
33
22
Working Capital
1
- -
- -
- -
2
2
1
2
8
2
1
- -
12
11
10
LT Debt
-1
1
2
16
8
15
22
18
12
151
142
115
87
48
23
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
135.89
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
334.73
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-10.12
-32.83
-56.9
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
105.59%
-29.05%
-51.19%
Free Cash Flow
-935.33%
-62.04%
-10.21%
Net Income, GAAP
-236.42%
13.9%
-45.2%
Sales/Revenue/Turnover
227.64%
-21.31%
2.03%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
11
2024
- -
- -
- -
- -
20
2025
- -
- -
- -
- -
20

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.4
2024
- -
- -
- -
- -
-0.59
2025
- -
- -
- -
- -
-0.32

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Titan Medical Inc. (TMDI)
Mentice AB (publ) (MNTC.ST)
Senzime AB (publ) (SNZZF)
Profound Medical Corp. (PROF)
Therma Bright Inc. (TBRIF)
Erech Finance (EFNC-M.TA)
Business
Novacyt S.A. (NVYTF) is an international molecular diagnostics company that develops, manufactures and commercialises molecular assays, workflows and instrumentation for clinical, research and instrumentation applications across human health, animal health and environmental sectors; its clinical portfolio targets reproductive health with non-invasive prenatal testing (NIPT), cystic fibrosis and rapid aneuploidy assays, precision medicine including DPYD genotyping, and infectious diseases such as the Winterplex multiplex respiratory PCR panel; the instrumentation segment features Ranger Technology for automated DNA sample preparation and target enrichment, alongside genesig q16 and q32 real-time qPCR instruments; research use only offerings encompass high-performance qPCR assays for human health, agriculture, veterinary and environmental applications, plus pharmaceutical services like whole genome and exome sequencing. The company operates through brands including Primerdesign, founded in 2005 and specialising in real-time PCR kits and reagents supplied to customers in over 100 countries, and Yourgene Health, providing NIPT NGS workflows, PCR assays and Ranger platforms for applications in NIPT, liquid biopsy, oncology and gene synthesis. Headquartered in Le Vésinet, France, with key facilities in Manchester, UK, and offices in Singapore, the US and Canada, Novacyt maintains a commercial presence in over 65 countries and lists on the London Stock Exchange AIM (NCYT) and Euronext Growth Paris (ALNOV). In recent developments, the company completed integration of its 2023 Yourgene Health acquisition ahead of schedule, delivering £5.0 million in cost synergies within 18 months and achieving £3.0 million in additional annual EBITDA improvements from site consolidations including the closure of IT-IS International, relocation of Canadian and Primerdesign manufacturing to Manchester by early 2025; it disposed of its Taiwanese laboratory business, reclaimed £12.2 million in VAT post-DHSC settlement, received EU IVDR accreditation for key assays like Yourgene QST*R Base and Cystic Fibrosis Base, launched norovirus detection for oysters and mpox clade assays, expanded veterinary multiplex panels, supported new NIPT labs in Colombia and Kazakhstan, and plans four 2025 product launches in reproductive health, precision medicine and Ranger Technology backed by £2.0 million extra R&D investment; board changes included appointing Lyn Rees as CEO, Steve Gibson as CFO, Dr Jo Mason as CSO, Dr John Brown as Chairman and Dr Ian Gilham as non-executive director.

Company News

APIChatGPT